• Clearside Biomedical, Inc. (NASDAQ:CLSD) showcases a Return on Invested Capital (ROIC) of 56.84%, significantly outperforming its competitors in the biopharmaceutical sector.
• The company's ROIC to WACC ratio of 3.19 indicates efficient capital utilization, making it an attractive option for investors.
• Competitors like Cidara Therapeutics, Leap Therapeutics, and Selecta Biosciences display negative or lower ROIC to WACC ratios, highlighting Clearside's superior financial performance.

Clearside Biomedical, Inc. (NASDAQ:CLSD) is a biopharmaceutical company focused on developing therapies to treat eye diseases. The company uses its proprietary SCS Microinjector to deliver drugs to the back of the eye, aiming to improve treatment outcomes. In the competitive landscape, Clearside competes with other biopharmaceutical companies like Cidara Therapeutics, Leap Therapeutics, and Selecta Biosciences.

Clearside's Return on Invested Capital (ROIC) is 56.84%, which is significantly higher than its Weighted Average Cost of Capital (WACC) of 17.84%. This results in a ROIC to WACC ratio of 3.19, indicating that the company is generating returns well above its cost of capital. This is a positive indicator for investors, as it suggests efficient capital utilization.

In comparison, Cidara Therapeutics (CDTX) has a negative ROIC of -37.65% and a WACC of 8.73%, resulting in a ROIC to WACC ratio of -4.32. This negative ratio indicates that Cidara is not generating sufficient returns to cover its cost of capital, which could be a concern for investors.

Leap Therapeutics (LPTX) also shows a negative ROIC of -143.45% against a WACC of 5.27%, leading to a ROIC to WACC ratio of -27.22. This suggests that Leap is struggling to generate returns on its invested capital, making it less attractive compared to Clearside.

Selecta Biosciences (SELB) has a ROIC of 7.68% and a WACC of 8.38%, resulting in a ROIC to WACC ratio of 0.92. While this is the highest among its peers, it still falls short of Clearside's performance. This comparison highlights Clearside's superior efficiency in generating returns relative to its cost of capital.